Metagenomi News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Metagenomi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Metagenomi Today - Breaking & Trending Today
JPMorgan Chase & Co. lowered shares of Metagenomi (NASDAQ:MGX – Free Report) from an overweight rating to a neutral rating in a report published on Thursday, MarketBeat.com reports. They currently have $6.00 target price on the stock, down from their prior target price of $16.00. A number of other equities research analysts have also issued […] ....
JPMorgan Chase & Co. cut shares of Metagenomi (NASDAQ:MGX – Free Report) from an overweight rating to a neutral rating in a research report report published on Thursday morning, MarketBeat.com reports. They currently have $6.00 price objective on the stock, down from their previous price objective of $16.00. Several other brokerages also recently commented on […] ....
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will prese ....
Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) has earned an average rating of “Buy” from the six ratings firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $21.40. […] ....
Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) major shareholder Holdings A/S Novo bought 800,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $12,000,000.00. Following the transaction, the insider now directly owns 1,739,175 […] ....